Thor Medical

Mindre end 1K følgere

TRMED

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Thor Medical is a pharmaceutical company. The company specializes in the development of antibody drugs for the treatment of hematological cancer. The greatest specialization is found in precision therapy used in the clinical phase. Other diseases that are treated are non-Hodgkin's lymphoma (NHL). The company was founded in 2009 and is headquartered in Oslo, Norway.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

29.8

2025

Delårsrapport Q2'25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse13.5.2025, 14.45

TRMED: Thor Medical sign strategic supply agreement for feedstock of thorium

Selskabsmeddelelse2.5.2025, 21.06

Thor Medical - Primary insider notifications - Grant of restricted stock units (RSU) to the members of the board

Selskabsmeddelelse2.5.2025, 17.55

Thor Medical - Grant of restricted stock units (RSU) to the members of the board

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse24.4.2025, 13.03

Thor Medical ASA: Completion of annual general meeting

Selskabsmeddelelse11.4.2025, 16.27

TRMED: Flagging Thor Medical ASA 11 April 2025

Selskabsmeddelelse9.4.2025, 13.19

Thor Medical ASA: Notification of trade for close associates of primary insider

Selskabsmeddelelse4.4.2025, 08.52

Thor Medical ASA: Notification of trade for close associates of primary insider

Selskabsmeddelelse3.4.2025, 06.38

Thor Medical ASA - Notice of Annual General Meeting on 24 April 2025

Selskabsmeddelelse28.3.2025, 06.00

TRMED: Thor Medical ASA publishes Annual report 2024

Selskabsmeddelelse25.3.2025, 15.46

Thor Medical makes final investment decision for AlphaOne - ready for commercial production in 2026

Selskabsmeddelelse26.2.2025, 06.00

Thor Medical ASA interim and full-year 2024 results - closing in on commercial launch

Selskabsmeddelelse20.2.2025, 07.00

TRMED: Invitation to presentation of Thor Medical ASA's second half and full year results 2024

Selskabsmeddelelse10.2.2025, 08.25

Thor Medical ASA: Share capital increase in relation to Subsequent Offering registered

Selskabsmeddelelse24.1.2025, 19.17

Thor Medical ASA: Notification of trade for close associate of primary insider

Selskabsmeddelelse24.1.2025, 19.00

Thor Medical ASA: Final results of the Subsequent Offering

Selskabsmeddelelse24.1.2025, 06.00

Thor Medical ASA: The Subscription Period in the Subsequent Offering ends today at 12:30 CET

Selskabsmeddelelse16.1.2025, 15.27

TRMED: Financial calendar

Selskabsmeddelelse15.1.2025, 09.31

Thor Medical ASA: Share capital increase in relation to Tranche 2 of the Private Placement is registered

Selskabsmeddelelse13.1.2025, 06.00

Thor Medical ASA: Commencement of the subscription period for the subsequent offering

Selskabsmeddelelse10.1.2025, 12.30

Thor Medical ASA: Approval of prospectus and launch of subsequent offering

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.